SCHEMBL21097708

SCHEMBL21097708

CCc1ccc(N2CCC(N)CC2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.47
SKP1 P63208 1/20 0.47
SKP2 Q13309 1/20 0.47
HRH3 Q9Y5N1 5/20 0.45
GPR119 Q8TDV5 1/20 0.44
LCAT P04180 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
HTR3E A5X5Y0 1/20 0.42
MEN1 O00255 1/20 0.42
HTR3B O95264 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
HTR3A P46098 1/20 0.42
KMT2A Q03164 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42
MAPT P10636 1/20 0.40
RET P07949 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10331958 0.84 LCAT (0.47) HRH3GPR119LCATCYP1A2CYP2D6
SCHEMBL16812024 0.83 CKS1B (0.41) CKS1BSKP1SKP2HRH3CYP1A2
SCHEMBL24240446 0.82 MAP4K4 (0.47) HRH3RETHRH4
SCHEMBL18404004 0.82 MCHR1 (0.48) HRH3GPR119LCATCYP2D6MAPT
SCHEMBL9908392 0.82 HRH3 (0.53) HRH3CYP1A2CYP2D6MAPTAOC3
SCHEMBL12217555 0.82 HRH3 (0.49) HRH3GPR119CYP1A2CYP2D6MAPT
SCHEMBL12127778 0.81 L3MBTL3 (0.47) HRH3GPR119LCATCYP1A2CYP2D6
SCHEMBL8429477 0.80 CYP1A2 (0.54) HRH3CYP1A2CYP2D6MAPTAOC3
SCHEMBL26703747 0.80 HRH3 (0.46) HRH3GPR119
SCHEMBL16769756 0.80 LMNA (0.46) HRH3GPR119LCATMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11541126-B1 Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof SILVERBACK THERAPEUTICS, INC. (US) 2023-01-03 US disclosed
WO-2019118884-A1 ANTIBODY CONSTRUCT-DRUG CONJUGATE FOR THE TREATMENT OF HEPATITIS SILVERBACK THERAPEUTICS, INC. (US) 2019-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541126-B1 Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof ASGR1, TLR8, HAVCR2 CKS1B 4229/4885SKP1 4557/4885SKP2 4279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.